| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Feb―03 |
New target to tackle coronaviruses |
Sarah Crunkhorn |
| 2 |
[GO] |
2024―Dez―02 |
Antiviral target compound profile for pandemic preparedness |
James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A. T. Young, Richa Chandra, et al. (+15) Sujata Vaidyanathan, Margaret Chu-Moyer, Christopher L. Lynch, Andrew Campbell, Kumar Singh Saikatendu, John P. Bilello, Yoshihiko Murata, Marnix van Loock, Aeron C. Hurt, Timothy Tellinghuisen, Lee Ruggiero, Richard Mackman, Nina M. Hill, John C. Pottage, Marnix van Loock |
| 3 |
[GO] |
2024―Okt―29 |
Antibody vanquishes SARS-CoV-2 variants |
Katie Kingwell |
| 4 |
[GO] |
2024―Sep―27 |
Targeting fibrin in COVID-19 |
Sarah Crunkhorn |
| 5 |
[GO] |
2023―Dez―01 |
Open-science drug discovery for COVID-19 |
Sarah Crunkhorn |
| 6 |
[GO] |
2023―Mai―12 |
Accelerating antiviral drug discovery: lessons from COVID-19 |
Annette von Delft, Matthew D. Hall, Ann D. Kwong, Lisa A. Purcell, Kumar Singh Saikatendu, Uli Schmitz, et al. (+2) John A. Tallarico, Alpha A. Lee |
| 7 |
[GO] |
2023―Apr―19 |
Therapeutic strategies for COVID-19: progress and lessons learned |
Guangdi Li, Rolf Hilgenfeld, Richard Whitley, Erik De Clercq |
| 8 |
[GO] |
2023―Apr―05 |
Host-directed antiviral blocks SARS-CoV-2 entry |
Sarah Crunkhorn |
| 9 |
[GO] |
2023―Jan―13 |
2022 FDA approval number dips: a COVID-19 hangover? |
Mathias Baedeker, Michael S. Ringel, Clemens C. Möller, Ulrik Schulze |
| 10 |
[GO] |
2022―Dez―14 |
Closing the door to SARS-CoV-2 |
Sarah Crunkhorn |
| 11 |
[GO] |
2022―Okt―28 |
Pandemic vaccines: a formidable challenge for pharmacovigilance |
Alexandre Kiazand, Ruth Luther, Jessica Mårlind Würtele, Noel Southall, Douglas Domalik, Magnus Ysander |
| 12 |
[GO] |
2022―Jul―06 |
What should go into a booster shot for COVID-19? |
Asher Mullard |
| 13 |
[GO] |
2022―Jun―17 |
From pandemic preparedness to public-private partnerships |
Asher Mullard |
| 14 |
[GO] |
2022―Jan―28 |
A call to action for translational sciences in COVID-19 and future pandemics |
Kanny K. Wan, Danielle Davis, Taylor N. Lee, Stephanie L. Ford-Scheimer, Antonio L. Andreu, Florence Bietrix, et al. (+16) Justin Bryans, Marco T. Castro, Nobuyoshi Chiba, Jessica M. Faupel-Badger, Brittany Haynes, Ryutaro Hirasawa, Carlos M. Morel, Thiago Moreno L. Souza, David Morrow, Trent Munro, Stuart Newman, Anton E. Ussi, Poliana B. Zorzal, Matthew D. Hall, Donald C. Lo, Christine M. Cutillo |
| 15 |
[GO] |
2022―Jan―17 |
2021 FDA approvals: value driven by COVID-19 vaccines |
Mathias Baedeker, Michael S. Ringel, Ulrik Schulze |
| 16 |
[GO] |
2021―Dez―07 |
Choosing drugs for UK COVID-19 treatment trials |
Patrick F. Chinnery, Marion Bonnet, Alison Cave, Matthias P. Hofer, Alastair Lamb, Glenn A. McConkey, et al. (+6) Nicholas Medcalf, Stephen P. Smith, Teresa Tsakok, Robert Watson, Steve Webster, Tao You |
| 17 |
[GO] |
2021―Dez―06 |
Interfering viral-like particles inhibit SARS-CoV-2 replication |
M. Teresa Villanueva |
| 18 |
[GO] |
2021―Dez―02 |
A tale of two antiviral targets - and the COVID-19 drugs that bind them |
Megan Cully |
| 19 |
[GO] |
2021―Sep―09 |
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders |
Pei-Tzu Huang, Shirit Einav, Christopher R. M. Asquith |
| 20 |
[GO] |
2021―Sep―06 |
Pfizer’s COVID-19 vaccine secures first full FDA approval |
Asher Mullard |
| 21 |
[GO] |
2021―Jun―17 |
COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO |
Asher Mullard |
| 22 |
[GO] |
2021―Mai―17 |
COVID-19 impact on oncology clinical trials: a 1-year analysis |
Samik Upadhaya, Jia Xin Yu, Jeffrey Hodge, Jay Campbell |
| 23 |
[GO] |
2021―Apr―20 |
Long COVID’s long R&D agenda |
Asher Mullard |
| 24 |
[GO] |
2021―Apr―16 |
RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape |
Asher Mullard |
| 25 |
[GO] |
2021―Mrz―11 |
FDA authorizes first single-shot COVID-19 vaccine |
Asher Mullard |
| 26 |
[GO] |
2021―Feb―25 |
Trends in COVID-19 therapeutic clinical trials |
Kevin Bugin, Janet Woodcock |
| 27 |
[GO] |
2021―Jan―15 |
2020 FDA approvals: momentum kept despite COVID-19, but value falls |
Mathias Baedeker, Michael Ringel, Ulrik Schulze |
| 28 |
[GO] |
2020―Dez―04 |
COVID-19 vaccines buoy hope |
Asher Mullard |
| 29 |
[GO] |
2020―Nov―10 |
Impact of COVID-19 on pharmaceutical external innovation sourcing |
Lucas Robke, Lotte Berghauser Pont, Jens Bongard, Stephan Wurzer, Katarzyna Smietana, Rachel Moss |
| 30 |
[GO] |
2020―Sep―18 |
Immuno-oncology drug development forges on despite COVID-19 |
Samik Upadhaya, Vanessa M. Hubbard-Lucey, Jia Xin Yu |
| 31 |
[GO] |
2020―Sep―10 |
Clinical trial recovery from COVID-19 disruption |
John Z. Xue, Katarzyna Smietana, Pawel Poda, Kevin Webster, Guang Yang, Gaurav Agrawal |
| 32 |
[GO] |
2020―Sep―04 |
Evolution of the COVID-19 vaccine development landscape |
Tung Thanh Le, Jakob P. Cramer, Robert Chen, Stephen Mayhew |
| 33 |
[GO] |
2020―Sep―03 |
COVID-19 must catalyse changes to clinical development |
Rod MacKenzie, Peter Honig, Judy Sewards, Robert Goodwin, Marie-Pierre Hellio |
| 34 |
[GO] |
2020―Aug―05 |
Anti-IL-6Rs falter in COVID-19 |
Asher Mullard |
| 35 |
[GO] |
2020―Aug―05 |
COVID-19 vaccine guidelines |
Asher Mullard |
| 36 |
[GO] |
2020―Jul―07 |
COVID-19 platform trial delivers |
Asher Mullard |
| 37 |
[GO] |
2020―Jun―16 |
Immune status could determine efficacy of COVID-19 therapies |
Megan Cully |
| 38 |
[GO] |
2020―Jun―08 |
First antibody against COVID-19 spike protein enters phase I |
Asher Mullard |
| 39 |
[GO] |
2020―Jun―08 |
COVID-19 vaccines start moving into advanced trials |
Asher Mullard |
| 40 |
[GO] |
2020―Mai―18 |
Impact of COVID-19 on oncology clinical trials |
Samik Upadhaya, Jia Xin Yu, Cristina Oliva, Megan Hooton, Jeffrey Hodge, Vanessa M. Hubbard-Lucey |
| 41 |
[GO] |
2020―Mai―14 |
Remote digital monitoring in clinical trials in the time of COVID-19 |
Jennifer C. Goldsack, Elena S. Izmailova, Joseph P. Menetski, Steven C. Hoffmann, Peter M.A. Groenen, John A. Wagner |
| 42 |
[GO] |
2020―Apr―09 |
The COVID-19 vaccine development landscape |
Tung Thanh Le, Zacharias Andreadakis, Arun Kumar, Raúl Gómez Román, Stig Tollefsen, Melanie Saville, Stephen Mayhew |
| 43 |
[GO] |
2020―Apr―08 |
COVID-19 brings drug development to a halt |
Asher Mullard |
| 44 |
[GO] |
2020―Apr―08 |
Coordinating the COVID-19 pipeline |
Asher Mullard |
| 45 |
[GO] |
2020―Feb―10 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |
Guangdi Li, Erik De Clercq |
